alexa Li DU | Bechman Research Institute of City of Hope
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 
 

Li DU

Li DU
Department of Molecular Medicine
Bechman Research Institute of City of Hope
Los Angels
USA
 
Biography

My name is Li Du and I am currently working as a staff scientist in Beckman Research Institute City of Hope. My research focuses on endocrine and hormone-related cancer. (Please refer to the attached resume for more details of my research and publications). I have reviewed several manuscripts for EES journals. I find that manuscript reviewing is very helpful for improving research experience and building my future academic career.

Research Interest

Targeting CSCs By Inhibiting SUMOylation (City of Hope) Evaluate the role of SUMOylation in colorectal cancer stemness Investigate the role of SUMOylation in breast cancer metastasis TR4 as Novel Target for Pituitary Tumor Therapy (UCLA) Identified expression profile of TR4 in different types of pituitary tumor Evaluated the effects of TR4 on pituitary tumor cell proliferation and hormone secretion in vitro (mouse corticotroph cell line & human pituitary tumor primary culture) Investigated the effects of TR4 on pituitary tumor growth and function in vivo (nude mice tumor model) HIV-1 integrase inhibitor screening and inhibiton mechanism research (Ph.D. thesis research at Shanghai Institute of Materia Medica) HIV-1 integrase (IN) catalyzes the integration of viral-DNA into host chromosome and is a critical drug target for developing anti-HIV drugs. Established an inhibitor-screening platform targeting the viral-DNA binding activity of HIV-1 IN based on SPR Discovered 4 lead compounds targeting HIV-1 IN with anti-viral activity (2 patents in China) Revealed 2 novel inhibitor-binding sites by site-directed mutagenesis(N-terminal domain & LEDGF-binding domain) Crystalized HIV-1 IN CCD (catalytic core domain) in complex with an inhibitor Curriculum Vitae 2Discovered the first anti-HIV compound targeting IN-LEDGF interaction (yeast two-hybrid assay and cellular assays)

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords